CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income (loss)	$ 756,000	$ 2,408,000
Adjustments to reconcile net income (loss) to net cash:
Stock compensation expense	351,000	343,000
Foreign exchange loss (gain)	13,000	11,000
Depreciation and amortization	927,000	926,000
Deferred income taxes	(524,000)	(2,775,000)
Non-cash R&D services	209,000	238,000
Other	(6,000)	68,000
Other changes in assets and liabilities:
Accounts receivable, net	(362,000)	74,000
Inventories	(153,000)	(408,000)
Costs in excess of billings and unbilled receivables	253,000	25,000
Prepaid expenses and other assets	42,000	188,000
Accounts payable	(447,000)	(197,000)
Accrued expenses and other liabilities	55,000	(480,000)
Deferred revenue	(20,000)	(129,000)
Net cash from operating activities	1,094,000	292,000
Cash flows from investing activities:
Purchases of property, plant and equipment	(1,788,000)	(455,000)
Purchase of intangibles	(65,000)	(78,000)
Net cash from investing activities	(1,853,000)	(533,000)
Cash flows from financing activities:
Proceeds from issuance of common stock	13,000	13,000
Principal payments on capital leases	(72,000)	(80,000)
Proceeds from (payments of) equipment line of credit, net	281,000	0
Proceeds from (payments of) bank and subordinated debt, net	(329,000)	(490,000)
Net cash from financing activities	(107,000)	(557,000)
Effect of exchange rates on cash and cash equivalents	(38,000)	(19,000)
Net change in cash and cash equivalents	(904,000)	(817,000)
Cash and cash equivalents, beginning	2,415,000	2,607,000
Cash and cash equivalents, ending	1,511,000	1,790,000
Supplemental disclosures of cash flow information:
Cash paid during the year for: Interest	109,000	136,000
Cash paid during the year for: Tax payments (refunds)	7,000	3,000
Non cash activities:
Assets purchased under capital leases	12,000	0
Recapitalization of Xcede - conversion of non controlling notes payable to preferred stock	0	(3,103,000)
Subsidiary stock options issued to settle liabilities	0	75,000
Subsidiary debt issued to fund research activities	$ 0	$ 500,000